Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Welcome to an office-based treatment that can restore* bladder function and quality of life for your OAB patients — without the side effects of medications† or potential self-catheterization.‡,1
The Medtronic NURO™ system delivers electrical pulses through a needle to stimulate the afferent fibers of the tibial nerve that runs posterior to the medial malleolus and extends to the sacral nerve plexus. This treatment is called Percutaneous Tibial Neuromodulation (PTNM), otherwise known as Percutaneous Tibial Neurostimulation (PTNS).
The NURO system is easy to use and manage in almost any practice setting.
Pay for sessions as you need them
Our pay-as-you-go model allows you to purchase single-use therapy session kits for your NURO device as you need them.
LEARN MOREFree your time to see other patients
NURO self-administers for 30 minutes while the patient remains comfortably seated.
WATCH VIDEORELIEF MADE EASIER
NURO is designed for your convenience with 2-day therapy session kit delivery, adjustable stimulation, and the ability to pause and resume a session.
GET STARTEDIdentify candidates for PTNM
Review diagnosis and treatment guidelines to identify patients who may benefit from PTNM therapy.
VIEW GUIDELINESGet started with NURO
You can start treating patients with the NURO System in just 4 easy steps.
START NOWRestored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.
Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.
While the NURO device was not used in the studies cited here, since it delivers equivalent stimulation therapy as the device used in the studies, a user can expect similar performance.
Peters, K. M., S. A. Macdiarmid, et al. (2009). Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 182(3): 1055-1061.